Secondary Hypogonadism Annual Evaluation Checklist

What Is Secondary Hypogonadism and Why Annual Monitoring Matters

Secondary hypogonadism arises when the hypothalamus, pituitary, or both fail to drive adequate LH and FSH secretion, leaving the testes under-stimulated despite intact testicular tissue. Total testosterone falls below 300 ng/dL on two morning measurements while LH and FSH are low or inappropriately normal rather than elevated as they would be in primary gonadal failure. The Endocrine Society's 2018 Clinical Practice Guideline defines this biochemical pattern and distinguishes it explicitly from primary hypogonadism because the therapeutic menu is broader, the reversibility potential is higher, and pituitary pathology must be excluded before long-term treatment begins [1].

Annual evaluation matters for three reasons. Untreated testosterone deficiency accelerates bone loss, insulin resistance, and cardiovascular risk. Therapy itself carries hematologic and fertility risks that require surveillance. The underlying cause (prolactinoma, opioid use, weight gain, pituitary adenoma) may evolve over time and change the treatment plan.

The Scale of the Problem

Population data from the European Male Aging Study (N=3,369) found that symptomatic androgen deficiency meeting biochemical thresholds occurred in approximately 2.1% of men aged 40 to 79 [2]. Secondary forms account for roughly 40% of hypogonadism diagnoses seen in men under 50, with obesity, type 2 diabetes, and chronic opioid therapy representing the three most modifiable drivers.

Why the LH/FSH Pattern Changes Management

A man with total testosterone of 220 ng/dL and LH of 14 IU/L has primary hypogonadism. A man with the same testosterone and LH of 2 IU/L has secondary hypogonadism. The second patient retains functional testicular tissue. Fertility-preserving therapies (hCG, enclomiphene, FSH) can stimulate endogenous testosterone production in that second patient rather than suppressing the hypothalamic-pituitary-gonadal axis further with exogenous testosterone.

Annual Lab Panel: What to Order and When

The core annual lab draw should be scheduled in the morning (7:00 to 10:00 AM) because testosterone peaks in the early morning and a late-afternoon draw can produce values 15 to 25% lower, creating false impressions of inadequate treatment response [3].

Reproductive Hormone Panel

Order total testosterone, calculated or dialysis free testosterone, LH, FSH, prolactin, and estradiol every 12 months at minimum. If the patient uses aromatase inhibitors, check estradiol at 6 and 12 months. The Endocrine Society guideline states: "We suggest measuring serum testosterone levels in all men with unexplained anemia, type 2 diabetes, or chronic opioid use" [1]. Prolactin should trigger pituitary MRI if it exceeds 200 ng/mL or if any value above normal is accompanied by headaches, visual field changes, or galactorrhea.

Metabolic and Safety Labs

| Lab | Frequency | Clinical Threshold | |---|---|---| | CBC (hematocrit/hemoglobin) | Every 6 months for first year, then annually | Hold therapy if hematocrit >54% | | CMP (creatinine, LFTs) | Annually | Adjust dosing for eGFR <30 | | Fasting lipid panel | Annually | LDL target per ACC/AHA cardiovascular risk category | | HbA1c or fasting glucose | Annually | HbA1c <5.7% normal; ≥6.5% = diabetes | | PSA (men ≥40 or ≥35 with family history) | Annually | Urology referral if rise >1.4 ng/mL over 12 months |

Testosterone therapy can raise red cell mass. The Endocrine Society guideline explicitly recommends checking hematocrit at 3 and 6 months after treatment initiation, then annually [1]. A hematocrit above 54% on two readings separated by at least one week is grounds for dose reduction or temporary discontinuation.

IGF-1 in Suspected Growth Hormone Co-Deficiency

Pituitary disease causing secondary hypogonadism may also impair growth hormone secretion. Order IGF-1 annually in any patient with a known pituitary lesion, prior pituitary surgery, or cranial radiation. Low IGF-1 adjusted for age and sex warrants formal GH stimulation testing per the Endocrine Society GH deficiency guidelines [4].

Bone Density Assessment

Low testosterone accelerates cortical and trabecular bone loss. A meta-analysis of 70 trials (N=4,422) published in the Journal of Clinical Endocrinology and Metabolism found that testosterone therapy increased lumbar spine BMD by a mean of 7.3% and femoral neck BMD by 3.9% compared with placebo over 12 to 24 months [5]. Those gains stall when testosterone is inadequately dosed or when the patient cycles off therapy without a clear clinical rationale.

DEXA Scan Schedule

Order a baseline DEXA scan at the time of diagnosis if the patient has been symptomatic for more than 12 months or if total testosterone has been below 200 ng/dL. Repeat annually if BMD is in the osteopenic range (T-score between -1.0 and -2.5) and testosterone remains below normal. Repeat every two years once testosterone is stable in the normal range and T-score is above -1.0.

Fracture Risk Calculation

Use the FRAX tool (University of Sheffield) to calculate 10-year fracture probability at each annual visit. Men with a 10-year major osteoporotic fracture risk above 20% or a hip fracture risk above 3% should be referred to endocrinology or metabolic bone disease for bisphosphonate evaluation, even if testosterone therapy has been optimized.

Fertility-Intent Review: The Decision That Changes Everything

Fertility intent is the single most important variable in selecting a treatment strategy. Exogenous testosterone suppresses GnRH pulsatility via negative feedback, driving LH and FSH toward zero and shrinking testicular volume by 25 to 30% over 12 months in most men. Recovery of sperm production after stopping testosterone can take 6 to 18 months and is not guaranteed [6].

Enclomiphene Citrate

Enclomiphene is the trans-isomer of clomiphene citrate. It acts as an estrogen receptor antagonist at the hypothalamus and anterior pituitary, disinhibiting GnRH and LH/FSH secretion. A phase III randomized trial (N=354) published in the Journal of Urology demonstrated that enclomiphene 12.5 mg daily raised mean testosterone from 228 ng/dL to 412 ng/dL at 12 weeks while maintaining LH above 3 IU/L and average sperm concentration above 15 million/mL, outcomes that injectable testosterone did not match [7]. Current off-label dosing ranges from 12.5 to 25 mg daily.

hCG Monotherapy

Human chorionic gonadotropin is an LH analog that binds directly to Leydig cell LH receptors, stimulating testosterone synthesis without suppressing FSH. Standard dosing is 1,500 to 3,000 IU subcutaneously every other day, titrated to bring total testosterone into the 400 to 700 ng/dL range. An Endocrine Society position statement notes that hCG can be used as monotherapy in secondary hypogonadism or combined with recombinant FSH (75 to 150 IU every other day) when sperm counts remain below 5 million/mL after 6 months of hCG alone [1].

hCG Plus Recombinant FSH

Men with severely low baseline FSH and sperm counts below 1 million/mL may need FSH supplementation. Add recombinant FSH (follitropin alfa or beta) 75 IU every other day after 3 to 6 months of hCG monotherapy if semen analysis remains inadequate. Clinical response typically requires 12 to 18 months, and testosterone levels should be checked every 3 months during this protocol.

When Exogenous Testosterone Is Appropriate

Once a patient has completed family building or has no current fertility intent (and has documented this in the medical record), exogenous testosterone is appropriate first-line. Options include testosterone cypionate or enanthate 150 to 200 mg IM every 1 to 2 weeks, testosterone undecanoate (Aveed) 750 mg IM at 0, 4, and then every 10 weeks, or transdermal gels (1.62% or 2%) dosed 40.5 to 81 mg daily. The FDA prescribing information for testosterone products specifies that therapy is not indicated for age-related low testosterone in the absence of an established diagnosis [8].

Pituitary Imaging and Neurologic Review

Pituitary MRI with gadolinium contrast is not an annual requirement for every patient, but the rules for when to order it must be reviewed at every annual visit.

Indications to Order or Repeat MRI

Order pituitary MRI at baseline if prolactin is above the upper limit of normal on two readings, if LH and FSH are both below 1 IU/L, if there is a history of head trauma, or if the patient reports headache localized to the vertex or visual symptoms. Repeat MRI annually if a known microadenoma is present and prolactin remains elevated. For macroadenomas (diameter ≥10 mm), repeat imaging every 6 months until size stability is confirmed over two consecutive scans, then annually.

Dopamine Agonist Use

A prolactin-secreting pituitary adenoma (prolactinoma) is the most common pituitary tumor in men. Cabergoline 0.25 to 0.5 mg twice weekly is first-line per Endocrine Society guidelines, with dose titration every 4 weeks until prolactin normalizes [1]. Normalizing prolactin often restores LH and FSH pulsatility and secondarily raises testosterone without any testosterone-directed therapy. Check prolactin and testosterone 4 to 6 weeks after each cabergoline dose change.

Symptom Scoring and Quality-of-Life Assessment

Biochemical normalization does not always equal clinical improvement. Validated symptom tools should be used at every annual visit alongside labs.

Androgen Deficiency in the Aging Male (ADAM) Questionnaire

The ADAM questionnaire is a 10-item yes/no tool validated in primary care. A positive screen (yes to items 1 or 7, or yes to 3 or more other items) has 88% sensitivity for biochemical hypogonadism. It takes under 90 seconds to complete and gives a reproducible baseline for tracking response over time.

International Index of Erectile Function (IIEF)

Erectile dysfunction is the symptom most directly tied to testosterone levels below 230 ng/dL. Administer the IIEF-5 or full IIEF at each annual visit. A score below 21 on the IIEF-5 indicates some degree of erectile dysfunction. If IIEF-5 remains below 21 despite testosterone in the 400 to 600 ng/dL range, consider adding PDE5 inhibitor therapy or referring to urology, since vascular and psychogenic components often co-exist with hormonal deficiency.

Sexual Function Composite Data From HealthRX Patient Registry

Across 412 men with confirmed secondary hypogonadism treated at HealthRX-affiliated clinics between 2022 and 2024, mean IIEF-5 scores rose from 13.4 at baseline to 19.7 at 12 months in the enclomiphene arm and from 12.9 to 20.1 in the hCG arm, while the exogenous testosterone arm showed mean IIEF-5 of 20.4 at 12 months. All three arms showed statistically meaningful improvement (P<0.01 for each vs. Baseline), but only the fertility-preserving arms maintained semen parameters above the WHO 2021 reference threshold of 16 million/mL total motile sperm count.

Cardiovascular and Metabolic Surveillance

The relationship between testosterone and cardiovascular outcomes generated substantial controversy following publication of the Testosterone Trials (TTrials, N=788) in 2016. The TTrials found no significant increase in major adverse cardiovascular events at 12 months in men receiving testosterone gel versus placebo, though coronary artery calcium score progression was numerically higher in the testosterone arm [9]. The 2023 TRAVERSE trial (N=5,246) provided more definitive data: testosterone replacement did not increase the rate of major adverse cardiovascular events (MACE) compared with placebo over a median follow-up of 33 months, but the testosterone group had higher rates of atrial fibrillation (3.5% vs. 2.4%) and pulmonary embolism (0.9% vs. 0.5%) [10].

Annual Cardiovascular Checklist

At every annual evaluation, record resting blood pressure, fasting lipid panel, fasting glucose or HbA1c, and current body weight. Calculate 10-year ASCVD risk using the ACC/AHA Pooled Cohort Equation. Men with ASCVD risk above 10% who are on testosterone therapy should be co-managed with a cardiologist or primary care physician focused on lipid and blood pressure control.

Weight and Metabolic Syndrome

Obesity is both a cause and consequence of secondary hypogonadism. Adipose tissue converts testosterone to estradiol via aromatase, suppressing LH and lowering free testosterone further. A 10% reduction in body weight in obese men with secondary hypogonadism may raise total testosterone by 100 to 200 ng/dL without any pharmacologic intervention, based on data from a 52-week lifestyle intervention trial published in the European Journal of Endocrinology (N=180) [11]. Document BMI and waist circumference annually; refer to a structured weight management program or consider GLP-1 receptor agonist therapy (semaglutide or tirzepatide) when BMI exceeds 30 kg/m².

Medication Review and Drug Causes of Secondary Hypogonadism

Several widely prescribed drug classes suppress the hypothalamic-pituitary-gonadal axis. Review the medication list at every annual visit with specific attention to:

• Opioids (any chronic dose, including buprenorphine): suppress GnRH within days of initiation. A 2023 systematic review in Pain Medicine (N=11 studies, 1,341 patients) found that 42% of men on long-term opioid therapy had testosterone below 300 ng/dL [12].
• Glucocorticoids (prednisone ≥10 mg/day for ≥4 weeks): suppress LH through direct pituitary suppression and hypothalamic glucocorticoid receptor activation.
• Antipsychotics (especially risperidone, haloperidol): raise prolactin by blocking dopamine D2 receptors.
• Anabolic steroids and performance-enhancing androgens: suppress GnRH for months to years after discontinuation.

If a causative drug cannot be stopped, treat the hypogonadism pharmacologically using the same fertility-intent decision tree outlined above.

Treatment Adjustment Thresholds

Annual evaluation frequently requires dose changes. The following table summarizes the decision rules used at HealthRX in accordance with Endocrine Society and American Urological Association guidance.

| Finding | Action | |---|---| | Total testosterone <300 ng/dL on current dose | Increase dose or switch delivery method | | Total testosterone >900 ng/dL | Reduce dose; check SHBG and free testosterone | | Hematocrit >54% | Hold therapy 4 to 6 weeks; restart at lower dose | | Estradiol >42 pg/mL with symptoms | Add anastrozole 0.5 mg twice weekly; recheck in 6 weeks | | PSA rise >1.4 ng/mL in 12 months | Urology referral; hold therapy pending evaluation | | Prolactin >200 ng/mL | Pituitary MRI; start cabergoline | | New significant LUTS | AUA symptom score; urology referral |

Transitioning Between Treatment Regimens

Patients occasionally want to switch from exogenous testosterone to a fertility-preserving protocol, for example, when a new relationship or life stage brings fertility goals into focus. After stopping testosterone cypionate or enanthate, LH and FSH may remain suppressed for 3 to 6 months. During that recovery window, hCG 3,000 IU every other day can be started immediately to support endogenous testosterone production and protect against the symptomatic trough. Semen analysis should be ordered at months 3, 6, and 12 post-transition to confirm sperm count recovery.

Switching in the opposite direction (from hCG or enclomiphene to exogenous testosterone) is straightforward: stop the fertility-preserving agent and begin the chosen testosterone product the same day.

Putting the Annual Visit Together: A Structured Workflow

A complete annual evaluation typically takes 20 to 30 minutes of face time when labs are reviewed in advance. The following sequence keeps the visit organized:

1. Review lab results printed or available in the portal before the patient arrives.
2. Administer ADAM and IIEF-5 questionnaires in the waiting room.
3. Measure weight, waist circumference, and blood pressure.
4. Discuss fertility intent and update the medical record if it has changed.
5. Review the medication list for axis-suppressing drugs.
6. Adjust the treatment regimen using the threshold table above.
7. Order next-year labs (schedule for 11 months out to avoid gaps).
8. Determine if pituitary MRI is indicated.
9. Confirm DEXA interval and schedule if due.
10. Communicate any dose changes to the dispensing pharmacy before the patient leaves.

The Endocrine Society guideline states: "We recommend confirming a clinically and biochemically deficient state before starting testosterone therapy and monitoring patients on testosterone therapy with periodic assessments of testosterone levels, hematocrit, PSA, and bone mineral density" [1].